

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 October 2016 (13.10.2016)



(10) International Publication Number
WO 2016/164675 A8

(51) International Patent Classification:

C07D 403/12 (2006.01) C07D 409/12 (2006.01)
C07D 401/14 (2006.01) C07D 239/74 (2006.01)
C07D 405/14 (2006.01) C07D 239/94 (2006.01)
C07D 401/04 (2006.01) C07D 239/95 (2006.01)
C07D 401/12 (2006.01) C07D 413/12 (2006.01)
C07D 403/04 (2006.01) C07D 417/04 (2006.01)
C07D 403/14 (2006.01) C07D 471/08 (2006.01)
C07D 405/12 (2006.01)

(30) Priority Data:

62/145,705 10 April 2015 (10.04.2015) US
62/145,818 10 April 2015 (10.04.2015) US
62/255,891 16 November 2015 (16.11.2015) US
62/265,320 9 December 2015 (09.12.2015) US
62/265,316 9 December 2015 (09.12.2015) US

(21) International Application Number:

PCT/US2016/026573

(22) International Filing Date:

8 April 2016 (08.04.2016)

(25) Filing Language:

English

(26) Publication Language:


English

(71) Applicant: **ARAXES PHARMA LLC** [US/US]; 11119 North Torrey Pines Road, Suite 125, La Jolla, California 92037 (US).

(72) Inventors: **LI, Liansheng**; 13569 Arroyo Dale Lane, San Diego, California 92130 (US). **FENG, Jun**; 6160 Quail Run Street, San Diego, California 92130 (US). **LONG, Yun Oliver**; 10763 Santa Tomasa Ave., San Diego, California 92127 (US). **LIU, Yuan**; 3871 Camino Lindo, San Diego, California 92122 (US). **WU, Tao**; 2355 Terraza Guitara, Carlsbad, California 92009 (US). **REN, Pingda**; 5534 Havenridge Way, San Diego, California 92130 (US).

[Continued on next page]

(54) Title: SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF



(57) Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R^1 , R^{2a} , R^{2b} , R^{2c} , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^{5a} , R^{5b} , R^6 , A, B, G^1 , G^2 , L^1 , L^2 , m^1 , m^2 , n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.




FIG. 1



LIU, Yi; 4841 Barlows Landing Cove, San Diego, California 92130 (US).

(74) **Agents:** HARWOOD, Eric, A. et al.; Seed Intellectual Property Law Group PLLC, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(48) **Date of publication of this corrected version:**

11 May 2017

(15) **Information about Correction:**

see Notice of 11 May 2017